NEW YORK – Yourgene Health said on Tuesday that its Taiwanese subsidiary Yourgene Health Taipei has signed a regional marketing and services agreement for a genomic nasopharyngeal carcinoma screening test from Hong Kong-based Take2 Health.
Under the agreement, Yourgene will promote and distribute the Take2 Prophecy test in Taiwan and will establish a clinical network for the collection of patient blood samples. Additionally, the companies have signed a memorandum of understanding to consider granting Yourgene exclusive rights to deliver the Take2 Prophecy test in Taiwan and run the test out of its Taipei laboratory.
Take2 licensed the test methodology last year from Grail, which had obtained the rights when it merged with Hong Kong startup Cirina in 2017. The test method was originally developed by Dennis Lo and colleagues at the Chinese University of Hong Kong.
"This partnership is part of our expansion into the oncology market and precision medicine, and we look forward to working with Take2 on promoting the test and developing the service offering," Yourgene CEO Lyn Rees said in a statement.
Â